We are live on ! Find out more
ASLN

ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN

Delisted

ASLN was delisted on the 18th of July, 2024.

Back to rankings

41 hedge funds and large institutions have $88.7M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

975% more capital invested

Capital invested by funds: $8.25M → $88.7M (+$80.4M)

242% more funds holding

Funds holding: 12 → 41 (+29)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

Holders
41
Holders Change
+29
Holders Change %
+241.67%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
5
Reduced
5
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$10.3M
2
VC
Vivo Capital
California
+$9M
3
O
OrbiMed
New York
+$7.98M
4
LGM
Logos Global Management
California
+$7.29M
5
MP
Mangrove Partners
Connecticut
+$6.9M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$2.48M
2
BFM
Boothbay Fund Management
New York
-$255K
3
Renaissance Technologies
Renaissance Technologies
New York
-$210K
4
Morgan Stanley
Morgan Stanley
New York
-$118K
5
UBS Group
UBS Group
Switzerland
-$2.03K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
26
Atom Investors
Texas
$273K +$258K +2,037 New
IC
27
Ikarian Capital
Texas
$243K -$2.48M -19,548 -39%
VF
28
Virtu Financial
New York
$208K +$152K +1,203 +347%
CL
29
CSS LLC
Illinois
$168K +$158K +1,250 New
SSA
30
Schonfeld Strategic Advisors
New York
$168K +$160K +1,260 New
Morgan Stanley
31
Morgan Stanley
New York
$148K -$118K -930 -46%
State Street
32
State Street
Massachusetts
$108K +$12.5K +99 +14%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$70K +$66.6K +526 New
JP Morgan Chase
34
JP Morgan Chase
New York
$47K +$44.1K +348 New
Two Sigma Advisers
35
Two Sigma Advisers
New York
$47K +$44.7K +353 New
EP
36
Eudaimonia Partners
Tennessee
$34K +$31.7K +250 New
LC
37
Lindbrook Capital
California
$17K +$15.8K +125 New
SPIA
38
Steward Partners Investment Advisory
New York
$8.38K +$7.98K +63 New
AF
39
Allworth Financial
California
$7K +$2.28K +18 +47%
Bank of America
40
Bank of America
North Carolina
$3K +$2.66K +21 New
UBS Group
41
UBS Group
Switzerland
$2K -$2.03K -16 -52%
1
2

ASLN Hedge Fund Activity: Q1 2021 in Review

41 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q1 2021, worth a combined $88.7M — up 975% from $8.25M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ASLN positions and 0 closed out — a net gain of 29 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $10.3M. The largest seller was Ikarian Capital, cutting an estimated $2.48M.

  • 41 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q1 2021, up from 12 in Q4 2020.
  • Funds reported $88.7M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q1 2021, up 975% quarter-over-quarter.
  • 29 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q1 2021 and 0 closed out, a net change of +29 holders.
  • The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q1 2021 was RTW Investments, an estimated $10.3M added.
  • The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q1 2021 was Ikarian Capital, an estimated $2.48M sold.

Based on aggregated 13F filings for Q1 2021.